Business context and reporting period
Issuer discrepancy: The supplied filing is for Sevion Therapeutics, Inc. and subsidiaries, not Eloxx Pharmaceuticals, Inc. The Form 10-Q covers the quarter and six months ended December 31, 2016 (Sevion fiscal 2017 Q2); it was filed February 10, 2017. Sevion describes itself as a development-stage therapeutics company focused on antibody platforms and candidates for cancer and immunological diseases. Its lead candidates SVN001 and SVN002 were in preclinical development.
Financial performance and position
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating loss | $1.51 million | $3.72 million |
| Net loss | $0.79 million | $1.72 million |
| Loss per common share | $0.04 | $0.08 |
| Cash used in operating activities | — | $1.01 million |
- For the six months, cash declined $661,615 to $149,193. The company reported a working-capital deficit of $564,446 and accumulated deficit of $117.38 million.
- Current liabilities were $764,198; total liabilities were $2.96 million. The company had $300,000 of unsecured notes payable, issued in November 2016 to related party OPKO Health, Inc. and an existing stockholder. Notes bear 5% interest, with principal and interest due 12 months after issuance.
- No operating margin is meaningful given zero revenue. The filing does not provide a clear liquidity runway beyond management’s estimate that cash on hand at December 31 would cover expenses through February 28, 2017.
Material changes versus prior comparable periods
- Six-month operating loss narrowed 24% from $4.91 million; quarterly operating loss narrowed 60% from $3.76 million. Lower G&A and R&D spending and the prior-year goodwill impairment contributed; current-period acquired R&D impairment partly offset the improvement.
- Revenue fell to zero from $75,000 for the six-month comparison and from $37,500 for the quarterly comparison.
- Six-month R&D expense decreased 59% to $488,000, and G&A decreased 21% to $780,000, largely reflecting cost reductions, staff and salary cuts, reduced research activity, and a move to a smaller facility.
- Cash used in operations was $1.01 million versus $2.12 million in the prior-year six-month period. The company raised $300,000 through notes; it also received $50,000 from a patent sale.
Outlook, risks, and unusual items
- Management said additional capital is needed to operate and expand research. Potential sources include debt or equity financing, strategic transactions, and licensing; none is assured. If financing is unavailable, the company may curtail development, license assets, seek a business combination or sale, cease operations, or enter bankruptcy.
- The filing states that conditions raise substantial doubt about the company’s ability to continue as a going concern. R&D spending had been temporarily reduced pending financing or a strategic transaction; management expected continued losses and could not predict when, if ever, the company would become profitable.
- A $2.6 million acquired-R&D impairment was recorded for the six months, including $1.0 million in the December quarter, following a decline in market value. The associated deferred tax liability was reduced by $1.04 million, producing a six-month income tax benefit of $1.04 million.
- Changes in fair value of stock-right and warrant liabilities generated $956,575 of income in the six months; the liabilities were reduced to zero after the related reset provisions were expected to expire before an equity financing. A $149,728 gain was recognized on the patent sale, comprising $50,000 cash and relief of a previously recorded liability.
- Disclosure controls were deemed ineffective because of an unremediated material weakness in reviewing accounting for equity-linked financial instruments. Management reported remediation steps underway. The filing also highlights development, regulatory, intellectual-property, financing, dilution, and limited-trading-market risks.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is Sevion Therapeutics, not Eloxx Pharmaceuticals.
- Verify financing after the reported date and the company’s ability to meet obligations beyond the stated February 28, 2017 cash runway.
- Review the going-concern disclosure, working-capital deficit, and terms and repayment status of the $300,000 notes.
- Assess the status and funding of SVN001, SVN002, and other research programs, given the disclosed reduction in R&D spending.
- Track remediation of the material weakness and review the assumptions behind acquired-R&D impairment and equity-linked instrument valuations.